Overview

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

Primary Objective: To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553 (REGN727) administered at 3 different injection sites in healthy subjects. Secondary Objectives: - To assess the pharmacodynamic effect of a single subcutaneous dose of alirocumab SAR236553 (REGN727) on serum low-density lipoprotein cholesterol and other lipids and apolipoproteins. - To assess the safety of a single subcutaneous dose of alirocumab SAR236553 (REGN727). - To assess the immunogenicity of a single subcutaneous dose of alirocumab SAR236553 (REGN727).

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Antibodies, Monoclonal